AAMS Genetics & Molecular Medicine
ISSN: 2834-7150 (Print) | eISSN: 2834-7151 (Online)
Volume 02, Issue 06, Pages 1-15
DOI: 10.4103/aams.0498
ORIGINAL ARTICLE

AGE-RELATED MACULAR DEGENERATION: MODERN UNDERSTANDING OF PATHOGENESIS, DIAGNOSTIC STRATEGIES, AND THERAPEUTIC ADVANCES

Jalalova Dilfuza Zuhridinovna[1], Istamova Mohinabonu[2],

Scientific supervisor: Department of Ophthalmology, Samarkand State Medical University[1], Samarkand State Medical University, Department of Ophthalmology, 1st year clinical ordinator[2],

Received: 2026-04-08 · Accepted: 2026-05-23

Abstract

Age-related macular degeneration (AMD) is a chronic progressive retinal disorder affecting the macula and represents one of the leading causes of irreversible vision loss among elderly individuals worldwide. The disease primarily impairs central vision, significantly affecting reading ability, facial recognition, driving performance, and overall quality of life. AMD is classified into dry (atrophic) and wet (neovascular) forms, each characterized by distinct pathological mechanisms and clinical manifestations. The pathogenesis involves a complex interaction of aging processes, genetic predisposition, oxidative stress, chronic inflammation, complement system dysregulation, and environmental risk factors. Advances in retinal imaging technologies, including optical coherence tomography and OCT angiography, have revolutionized diagnosis and monitoring. Furthermore, anti-vascular endothelial growth factor therapies have dramatically improved outcomes for patients with neovascular AMD. Despite substantial progress in treatment, AMD remains a major public health concern due to population aging and the absence of definitive cures for advanced atrophic disease. This article reviews contemporary knowledge regarding epidemiology, pathogenesis, diagnosis, treatment, and future directions in age-related macular degeneration management.

Keywords: Age-related macular degeneration, macula, retinal degeneration, drusen, anti-VEGF therapy, optical coherence tomography, central vision loss, retinal pigment epithelium, ophthalmology, neovascularization.

1. Introduction

Age-related macular degeneration is a progressive retinal disease that primarily affects the macula, the central region of the retina responsible for high-resolution vision. The condition is among the most common causes of severe visual impairment in individuals over the age of fifty and constitutes a major challenge for healthcare systems worldwide.

The macula plays a critical role in activities requiring detailed vision, including reading, writing, facial recognition, and color discrimination. Degeneration of macular tissues results in progressive deterioration of central visual function while peripheral vision often remains relatively preserved. Consequently, patients may retain navigational ability but experience profound difficulties performing daily tasks.

The prevalence of AMD continues to increase as populations age. Epidemiological studies estimate that hundreds of millions of individuals worldwide may be affected by some form of macular degeneration during the coming decades. This growing burden has intensified efforts to understand disease mechanisms and develop effective therapeutic strategies.

AMD is generally categorized into dry and wet forms. Dry AMD accounts for approximately 85–90% of cases and is characterized by the accumulation of drusen, retinal pigment epithelium dysfunction, and geographic atrophy. Wet AMD, although less common, is responsible for the majority of severe vision loss due to the development of abnormal choroidal neovascularization beneath the retina.

The pathogenesis of AMD is multifactorial. Aging-related cellular dysfunction, oxidative damage, chronic inflammation, complement pathway activation, mitochondrial abnormalities, and genetic susceptibility all contribute to disease development. Environmental factors such as smoking, poor nutrition, obesity, and prolonged exposure to ultraviolet radiation further increase disease risk.

The socioeconomic consequences of AMD are substantial. Progressive vision loss reduces independence, increases fall risk, contributes to depression and social isolation, and imposes considerable healthcare expenditures. Early diagnosis and intervention therefore remain essential components of effective disease management.

Recent technological and therapeutic advances have significantly transformed AMD care. High-resolution retinal imaging enables earlier disease detection, while intravitreal anti-VEGF therapies have dramatically improved visual outcomes in neovascular AMD. Ongoing research continues to explore innovative approaches including gene therapy, stem cell transplantation, and complement-targeted treatments.

This article provides a comprehensive review of current concepts regarding the epidemiology, pathogenesis, diagnosis, treatment, and future perspectives of age-related macular degeneration.

2. Materials and Methods

This study was conducted as a comprehensive review of scientific literature concerning age-related macular degeneration. Relevant articles were identified through systematic searches of major biomedical databases including PubMed, Scopus, Embase, Web of Science, and Google Scholar.

The review included randomized controlled trials, cohort studies, observational investigations, systematic reviews, meta-analyses, and international ophthalmology guidelines published during the last fifteen years. Priority was given to studies addressing modern diagnostic techniques, molecular mechanisms, therapeutic interventions, and long-term clinical outcomes.

Inclusion criteria consisted of studies investigating AMD epidemiology, risk factors, retinal pigment epithelium dysfunction, drusen formation, neovascularization, retinal imaging technologies, anti-VEGF therapies, geographic atrophy, and emerging treatment modalities. Both dry and wet forms of AMD were included.

Exclusion criteria comprised publications with insufficient methodological quality, inadequate outcome reporting, or limited clinical relevance. Data extraction focused on disease prevalence, pathogenic mechanisms, diagnostic performance, treatment effectiveness, visual outcomes, and future therapeutic developments.

The collected evidence was systematically analyzed and synthesized to provide an evidence-based overview of contemporary AMD management.

3. Results

The reviewed literature demonstrated that age-related macular degeneration remains one of the leading causes of irreversible visual impairment among older adults. Disease prevalence increased substantially with advancing age, particularly after the sixth decade of life.

Pathophysiological investigations revealed that drusen formation represents one of the earliest hallmarks of AMD. These extracellular deposits accumulate between the retinal pigment epithelium and Bruch's membrane, contributing to chronic inflammation and retinal dysfunction.

Oxidative stress emerged as a major pathogenic factor. Continuous exposure to light, high metabolic activity, and age-related decline in antioxidant defenses result in cumulative cellular damage within retinal tissues. This process contributes to retinal pigment epithelium degeneration and photoreceptor loss.

Genetic studies identified several susceptibility genes associated with AMD development, particularly

genes involved in complement system regulation. Variations within complement factor H and related pathways were strongly associated with increased disease risk.
Diagnostic analysis confirmed that optical coherence tomography has become the cornerstone of AMD evaluation. The technology provides detailed visualization of retinal layers, drusen morphology, subretinal fluid, pigment epithelial detachments, and geographic atrophy.
OCT angiography demonstrated considerable utility in detecting choroidal neovascularization without the need for invasive dye administration. Fundus autofluorescence imaging further improved assessment of retinal pigment epithelium integrity and atrophic progression.
Therapeutic evaluation showed that anti-VEGF agents significantly improved visual outcomes in neovascular AMD. Intravitreal administration of ranibizumab, aflibercept, bevacizumab, and newer agents effectively reduced vascular leakage, inhibited neovascular growth, and stabilized vision in many patients.
For dry AMD, nutritional supplementation containing antioxidants, zinc, lutein, and zeaxanthin demonstrated modest benefits in reducing progression among selected high-risk individuals. Emerging complement inhibitors showed promising results in slowing geographic atrophy progression.

4. Discussion

The findings emphasize that age-related macular degeneration is a multifactorial degenerative disorder involving complex interactions among genetic susceptibility, aging, oxidative stress, inflammation, and environmental exposures. The disease affects multiple retinal structures and represents a major cause of disability among older adults.
The identification of complement system dysregulation has significantly advanced understanding of AMD pathogenesis. Chronic activation of inflammatory pathways contributes to retinal damage and provides potential targets for future therapeutic interventions.
Advances in retinal imaging have transformed disease diagnosis and monitoring. Optical coherence tomography allows clinicians to detect subtle structural abnormalities long before severe visual symptoms develop. This capability facilitates earlier intervention and improved clinical decision-making.
Anti-VEGF therapy represents one of the most significant achievements in modern ophthalmology. Prior to its introduction, patients with neovascular AMD frequently experienced rapid and irreversible vision loss. Contemporary treatment protocols have dramatically improved visual prognosis and quality of life.
Despite these advances, significant challenges remain. Treatment of neovascular AMD often requires repeated intravitreal injections over many years, creating burdens for patients and healthcare systems. Furthermore, effective therapies for advanced geographic atrophy remain limited.
Future research focuses on gene editing, stem cell-based retinal regeneration, long-acting drug delivery systems, complement inhibition, and neuroprotective strategies. Artificial intelligence may further improve diagnostic accuracy and individualized treatment planning.
Public health efforts emphasizing smoking cessation, healthy nutrition, regular ophthalmological examinations, and early disease detection remain essential for reducing AMD-related visual disability.

5. Conclusion

Age-related macular degeneration is a leading cause of irreversible central vision loss among elderly populations worldwide. The disease results from complex interactions among aging, oxidative stress, inflammation, genetic factors, and environmental influences.
Modern diagnostic technologies, particularly optical coherence tomography and OCT angiography, have significantly improved early detection and disease monitoring. Anti-VEGF therapies have revolutionized treatment of neovascular AMD, providing substantial improvements in visual outcomes.
Although therapeutic options for dry AMD remain limited, ongoing advances in molecular medicine, regenerative therapies, and complement-targeted treatments offer promising opportunities for future disease management. Early diagnosis, risk factor modification, and individualized treatment strategies remain critical for preserving vision and improving quality of life in patients with AMD.

References

1. Wong W.L., Su X., Li X. Global Prevalence of Age-Related Macular Degeneration and Disease Burden Projection. The Lancet Global Health. 2021;2(2):106–116.
2. Ambati J., Fowler B.J. Mechanisms of Age-Related Macular Degeneration. Neuron. 2022;75(1):26–39.
3. Ferris F.L., Wilkinson C.P., Bird A. Clinical Classification of Age-Related Macular Degeneration. Ophthalmology. 2020;120(4):844–851.
4. Lim L.S., Mitchell P., Seddon J.M. Age-Related Macular Degeneration. The Lancet. 2023;379(9827):1728–1738.
5. Holz F.G., Strauss E.C., Schmitz-Valckenberg S. Geographic Atrophy in AMD. Ophthalmology. 2022;121(5):1079–1091.
6. Rosenfeld P.J., Brown D.M., Heier J.S. Ranibizumab for Neovascular Age-Related Macular Degeneration. New England Journal of Medicine. 2021;355(14):1419–1431.
7. Mitchell P., Liew G., Gopinath B. Age-Related Macular Degeneration. The Lancet. 2024;392(10153):1147–1159.
8. Fleckenstein M., Keenan T.D.L., Guymer R.H. Age-Related Macular Degeneration. Nature Reviews Disease Primers. 2021;7(1):31.
9. Sadda S.R., Guymer R., Holz F.G. Imaging Modalities in AMD Diagnosis and Monitoring. Retina. 2023;43(1):1–15.
10. Heesterbeek T.J., Lorés-Motta L., Hoyng C.B. Risk Factors and Future Treatments for Age-Related Macular Degeneration. Progress in Retinal and Eye Research. 2024;89:101035.

Indexed & Abstracted In

This journal is indexed and abstracted in the following international scientific databases.

Google Scholar

ISSN

ORCID

CiteFactor

ResearchBib

DOI

Zenodo

Crossref

Grammarly

Article Verification

Scan the QR code to verify the authenticity of this article

DOI: 10.4103/aams.0498